ES2555491T3 - Composiciones y métodos para la inhibición de la ruta de JAK - Google Patents

Composiciones y métodos para la inhibición de la ruta de JAK Download PDF

Info

Publication number
ES2555491T3
ES2555491T3 ES10701189.2T ES10701189T ES2555491T3 ES 2555491 T3 ES2555491 T3 ES 2555491T3 ES 10701189 T ES10701189 T ES 10701189T ES 2555491 T3 ES2555491 T3 ES 2555491T3
Authority
ES
Spain
Prior art keywords
ylamino
methyl
oxo
methylpyrimidin
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10701189.2T
Other languages
English (en)
Inventor
Hui Li
Thilo J. Heckrodt
Yan Chen
Darren John Mcmurtrie
Vanessa Taylor
Rajinder Singh
Pingyu Ding
Sambaiah Thota
Rose Yen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42091548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2555491(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2555491T3 publication Critical patent/ES2555491T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Dental Preparations (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Un compuesto de formula I:**Fórmula** o una sal del mismo, en el que: X e Y son cada uno independientemente O, S, S(O), SO2 o NR1; cada R1 es independientemente para cada aparición H, alquilo C1-6 opcionalmente sustituido, C(O)-alquilo C1-6, CO2- alquilo C1-6 o R50; cada R50 es C(R9)2-O-R10 o C(R9)2-S-R10; cada R9 es independientemente para cada aparición H, alquilo C1-6 opcionalmente sustituido, arilo C6-10 opcionalmente sustituido o arilalquilo C7-16 opcionalmente sustituido; o como alternativa, dos R9, junto con el carbono al que están unidos, forman un grupo cicloalquilo C3-8 opcionalmente sustituido o un heteroarilciclilo de 3-8 miembros opcionalmente sustituido 3-8; R10 es Ra o -P(O)(OR11)2; cada R11 es independientemente para cada aparición Ra o un grupo catiónico monovalente; o dos R11, junto con los átomos a los que están unidos, forman un grupo fosfato cíclico de 4-8 miembros, o dos R11 juntos representan un grupo catiónico divalente; el anillo A es un arilo C6-10 o un heteroarilo de 5-10 miembros; cada R2 es independientemente para cada aparición H, Re, Rb, Re sustituido con uno o más de los mismos o diferentes Ra y/o Rb, -ORe sustituido con uno o más de los mismos o diferentes Ra y/o Rb, -SRe sustituido con uno o más de los mismos o diferentes Ra y/o Rb, -C(O)Re sustituido con uno o más de los mismos o diferentes Ra y/o Rb, - N(Ra)Re en el que Re está sustituido con uno o más de los mismos o diferentes Ra y/o Rb, -S(O)2Re sustituido con uno o más de los mismos o diferentes Ra y/o Rb, -B(ORa)2, -B(N(Rc)2)2, -(C(Ra)2)m-Rb, -O-(C(Ra)2)m-Rb, -S-(C(Ra)2)m- Rb, -O-(C(Rb)2)m-Ra, -N(Ra)-(C(Ra)2)m-Rb, -O-(CH2)m-CH((CH2)mRb)Rb, -C(O)N(Ra)-(C(Ra)2)m-Rb, -O-(C(Ra)2)m- C(O)N(Ra)-(C(Ra)2)m-Rb,-N((C(Ra)2)mRb)2, -S-(C(Ra)2)m-C(O)N(Ra)-(C(Ra)2)m-Rb, -N(Ra)-C(O)-N(Ra) -(C(Ra)2)m-Rb25 , - N(Ra)-C(O)-(C(Ra)2)m-C(Ra)(Rb)2 o -N(Ra)-(C(Ra)2)m-C(O)-N(Ra)-(C(Ra)2)m-Rb; cada Ra es independientemente para cada aparición H, deuterio, alquilo C1-6, cicloalquilo C3-8, cicloalquilalquilo C4-11, arilo C6-10, arilalquilo C7-16, heteroalquilo de 2-6 miembros, heteroaliciclilo de 3-10 miembros, heteroaliciclilalquilo de 4-11 miembros, heteroarilo 5-15 miembros o heteroarilalquilo de 6-16 miembros; cada Rb es independientemente para cada aparición >=O, -ORa, -O-(C(Ra)2)m,-ORa, haloalquiloxi C1-3, >=S, -SRa, >=NRa, >=NORa, -N(Rc)2, halo, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, >=N2, -N3, -S(O)Ra, -S(O)2Ra, -SO3Ra, - S(O)N(Rc)2, -OS(O)Ra, -OS(O)2Ra, -OSO3Ra, -OS(O)2N(Rc)2, -C(O)Ra, -CO2Ra, -C(O)N(Rc)2, -C(NRa)-N(Rc)2, - C(NOH)-Ra, -C(NOH)-N(Rc)2, -OC(O)Ra, -OC(O)ORa, -OC(O)N(Rc)2, -OC(NH)-N(Rc)2, -OC(NRa)-N(Rc)2, - [N(Ra)C(O)]nRa, -[N(Ra)C(O)]nORa, -[N(Ra)C(O)]nN(Rc)2 o -[N(Ra)C(NRa)]n-N(Rc)2; cada Rc es independientemente para cada aparición Ra, o, como alternativa, se toman juntos dos Rc con el átomo de nitrógeno al que se enlazan para formar un heteroaliciclilo de 3 a 10 miembros o un heteroarilo de 5-10 miembros que opcionalmente puede incluir uno o más de los mismos o diferentes heteroátomos adicionales y que está opcionalmente sustituido con uno o más de los mismos o diferentes grupos Ra y/o Rd; cada Rd es >=O, -ORa, halo alquiloxi C1-3,alquilo C1-6, >=S, -SRa, >=NRa, >=NORa, -N(Ra)2, halo, -CF3, -CN, -NC, -OCN, - SCN, -NO, -NO2, >=N2, -N3, -S(O)Ra, -S(O2)Ra, -SO3Ra, -S(O)N(Ra)2, -S(O)2N(Ra)2, -OS(O)Ra, -OS(O)2Ra, -OSO3Ra, - OS(O)2N(Ra)2, -C(O)Ra, -CO2Ra, -C(O)N(Ra)2, -C(NRa)N(Ra)2, -C(NOH)Ra, -C(NOH)N(Ra)2, -OCO2Ra, -OC(O)N(Ra)2, -OC(NRa)N(Ra)2 -[N(Ra)C(O)]nRa, -(C(Ra)2)n-ORa, -N(Ra)-S(O)2Ra, -C(O)-haloalquilo C1-6, -S(O)2- haloalquilo C1-6, - OC(O)Ra, -O(C(Ra)2)m-ORa, -S(C(Ra)2)m-ORa, -N(Ra)-haloalquilo C1-6, -P(O)(ORa)2, -N(Ra)-(C(Ra)2)m-ORa, - [N(Ra)C(O)]nORa, -[N(Ra)C(O)]nN(Ra)2, -[N(Ra)C(NRa)]n(Ra)2 o -N(Ra)C(O)-haloalquilo C1-6; o dos Rd, tomados junto con el átomo o átomos a los que están unidos, se combinan para formar un anillo mono o bicíclico, parcial o totalmente saturado de 3-10 miembros, que contiene opcionalmente uno o más heteroátomos y está opcionalmente sustituido con uno o más Ra; cada Re es independientemente para cada aparición alquilo C1-6, cicloalquilo C3-8, cicloalquilalquilo C4-11, arilo C6-10, arilalcilo C7-16, heteroalquilo de 2-6 miembros, heteroaliciclilo de 3-10 miembros, heteroaliciclilalquilo de 4-11 miembros, heteroarilo de 5-15 miembros o heteroarilalquilo de 6-16 miembros; p es 0, 1, 2, 3 o 4; cada m es 1, 2 o 3; cada n es 0, 1,2 o 3; o dos grupos R2, tomados junto con el átomo o átomos a los que están unidos, se combinan para formar un anillo mono o bicíclico, parcial o totalmente saturado de 4-10 miembros, que contiene opcionalmente uno o más heteroátomos y está opcionalmente sustituido con uno o más Ra y/o Rb; Z1 y Z2 son cada uno independientemente CH, CR2 o N; R3 es H, alquilo C1-6 opcionalmente sustituido o R50; R4 es H, alquilo C1-6 opcionalmente sustituido o R50; y R5 es halo, -CN, alquilo C1-6 opcionalmente sustituido, alquinilo, hidroxi, alcoxi C1-6 opcionalmente sustituido, nitro, - N(Ra)2, -C(O)N(Ra)2, -CO2Ra o -C(O)Ra.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
5
10
15
20
25
30
35
40
45
CF3, -CN, -S(O)2N(Rc)2, -S(O)2Ra, -C(O)Ra, -CO2Ra, -C(O)N(Rc)2, -C(Ra)2-N(Rc)2 o -[N(Ra)C(O)]nRa; y uno de R2a y R2b no sea H. En otra realización, cada uno de R2a y R2b es H, alquilo C1-6, -ORa, -OCF3, halo, -N(Rc)2, -CF3, -C(Ra)2N(Rc)2 o -CN. En otra realización, R2b es -CF3 o -CH3; y R2a es halo o -CH3. En otra realización, R2a es H, -CH3, -CF3, -ORa o -OCF3; y R2b es -N(Rc)2 o -C(Ra)2-N(Rc)2. En otra realización más, R2a es -N(Rc)2 o -C(Ra)2-N(Rc)2; y R2b es H, -CH3, -CF3, -ORa o -OCF3.
Aún en otra realización es un compuesto de fórmulas estructurales IA1 o IA2, en las que R2c y R2d son H, y R5 es F o CH3; R2a y R2b se toman junto con los carbonos a los que están unidos para formar un anillo mono o bicíclico, parcial
o totalmente saturado de 4-10 miembros, que contiene opcionalmente uno o más heteroátomos y opcionalmente sustituido con uno o más Ra y/o Rb. En una realización, este es un anillo de 5 miembros, y en una realización más específica el anillo de 5 miembros es ciclopentano, pirrolidina, imidazolidina, 1,3-dioxolano, oxazolidina o tetrahidrofurano; opcionalmente sustituido con uno o más Ra y/o Rb. En una realización específica, el anillo de 5 miembros es pirrolidina, y en una realización incluso más específica los compuestos están de acuerdo con fórmula IA3:
imagen15
en la que Rb es OH, alquilo C1-6, -CO2-alquilo C1-6, -C(O)-alquilo C1-6 o -S(O)2-alquilo C1-6. En otra realización, R2a y R2b se toman junto con los carbonos a los que están unidos para formar un anillo monocíclico parcial o totalmente saturado de 6, 7 u 8 miembros, que contiene opcionalmente uno o más heteroátomos y opcionalmente sustituido con uno o más Ra y/o Rb. En una realización, cuando el anillo es de 6 miembros, el anillo es ciclohexano, morfolina, piperidina, dioxano, oxatiazinano o piperazina; opcionalmente sustituido con uno o más Ra y/o Rb. En otra realización, cuando el anillo es de 7 miembros, el anillo es cicloheptano, ciclohepteno, azepano, tetrahidroazepina o diazepano; opcionalmente sustituido con uno o más Ra y/o Rb. En otra realización más, cuando el anillo es de 8 miembros, el anillo es ciclooctano, cicloocteno, azocano, hexahidroazocina, diazocano o hexahidrodiazocina; opcionalmente sustituido con uno o más Ra y/o Rb. Para cada una de las realizaciones anteriores, en las que R2a y R2b se toman junto con los carbonos a los que están unidos para formar un anillo monocíclico parcial o totalmente saturado de 5, 6, 7 u 8 miembros, hay una realización más específica en la que hay 0, 1, 2 o 3 en cada uno de Ra y Rb, y Ra es alquilo C1-6; y cada Rb es independientemente para cada aparición =O, -ORa, haloalquiloxi C1-3, -SRa, N(Rc)2, halo, -CF3, -CN, -S(O)2Ra, -C(O)Ra, -CO2Ra, -C(O)N(Rc)2 o -C(Ra)2-N(Rc)2. Por ejemplo, en una realización, hay al menos un Rb que es =O; y opcionalmente un Ra que es alquilo C1-6 opcionalmente sustituido. Ejemplos particulares de compuestos de acuerdo con la fórmula IA3, incluyen, pero sin limitación, se abarcan compuestos tales como IV-2, IV-10, IV-14 a través de IV-16, IV-18 a través de IV-34 y IV-50 (véase Tabla IV).
Algunas realizaciones incluyen compuestos en los que el anillo A es otro distinto de fenilo. En una realización específica, el anillo A es piridina o piridazina. Como se muestra en la fórmula I, y con respecto a esta realización, la piridina o piridazina puede tener diversas configuraciones regioquímicas y puntos de unión a la molécula precursora.
imagen16
en los que las variables de definen de la misma manera como para los de fórmula I, y además: Q1 y Q2 son cada uno independientemente N o CR2, con la condición de que al menos uno de Q1 y Q2 sea N; X e Y son cada uno independientemente O o NR1; cada R1 es independientemente para cada aparición H, alquilo C1-6 opcionalmente sustituido o R50; p es 0, 1, 2 o 3; y R5 es halo, -CN, alquilo C1-6 opcionalmente sustituido, nitro, -N(Ra)2, -C(O)N(Ra)2, -CO2Ra o -C(O)Ra.
imagen17
en la que cada uno de R2a, R2b, R2c y R2d (cuando están presentes) es independientemente para cada aparición como se define para R2
16 5
10
15
20
25
30
35
40
45
50
55
Una realización es un compuesto de fórmula estructural IB1 o IB2, en la que X e Y son cada uno independientemente NR1. En una realización más específica, X e Y son cada uno independientemente NH o Nalquilo C1-6. EN una realización incluso más específica, X e Y son cada uno independientemente NH o NCH3. En una realización, en la que X e Y se definen más específicamente como se han mencionado, R5 es halo o alquilo C1-6; Z1 es CH, C-Halo o C-alquilo C1-6 opcionalmente sustituido; y Z2 es CH. En otra realización, R2a y R2d son H; y R5 es F o CH3. En otra realización, cada uno de R2b y R2c es independientemente para cada aparición H, alquilo C1-6, -ORa, -OCH2F, -OCF3, -SRa, -N(Rc)2, halo, -OCF2H, -CF3, -CN, -S(O)2Ra, -C(O)Ra, -CO2Ra, -C(O)N(Rc)2, -C(Ra)2-N(Rc)2 o [N(Ra)C(O)]nRa; y uno de R2b y R2c no es H. En tal otra realización, cada uno de R2b y R2c es independientemente para cada aparición H, alquilo C1-6, -N(Rc)2, halo, -CF3, -CN, -S(O)2Ra, -C(O)Ra, -CO2Ra, -C(O)N(Rc)2, o -C(Ra)2N(Rc)2. En otra realización, R2b es H, halo, -CF3, -CN o -CH3; y RZc es -N(Rc)2, -S(O)2Ra, -C(O)N(Rc)2 o -C(Ra)2N(Rc)2.
Otra realización es un compuesto de fórmula estructural IB1 o IB2, en la que X es O e Y es NR1. En una realización, R5 es halo o alquilo C1-6; Z1 es CH, C-Halo o C-alquilo C1-6 opcionalmente sustituido; y Z2 es CH. En otra realización, R2a y R2d son H; y R5 es F o CH3. En una realización más específica, cada uno de R2b y R2c es independientemente para cada aparición H, alquilo C1-6, -ORa, -OCF3, -SRa, -N(Rc)2, halo, -OCF2H, -OCH2F, -CF3, -CN, -S(O)2Ra, C(O)Ra, -CO2Ra, -C(O)N(Rc)2, -C(Ra)2-N(Rc)2 o -[N(Ra)C(O)nNRa; y uno de R2b y R2c no es H. En otra realización, cada uno de R2b y R2c es independientemente para cada aparición H, alquilo C1-6, -N(Rc)2, halo, -CF3, -CN, -S(O)2Ra, -C(O)Ra, -CO2Ra, -C(O)N(Rc)2, o -C(Ra)2-N(Rc)2. En una realización más específica R2b es H, halo, -CF3, -CN o -CH3; y R2c es -N(Rc)2, -S(O)2Ra, -C(O)N(Rc)2 o -C(Ra)2-N(Rc)2. En otra realización, R2b es H, halo, -CF3, -CN o -CH3; y R2c es -N(Rc)2 o -C(Ra)2-N(Rc)2.
Otra realización es un compuesto de fórmula estructural IB1 o IB2, en la que X es O; Y es NR1; Z1 es CH, C-Halo o C-alquilo C1-6 opcionalmente sustituido; Z2 es CH; R2a y R2d son H; y R5 es F o CH3, R2b y R2c se toman junto con los carbonos a los que están unidos para formar un anillo mono o bicíclico, parcial o totalmente saturado de 4-10 miembros, que contiene opcionalmente uno o más heteroátomos y opcionalmente sustituido con uno o más Ra y/o Rb. En una realización, el anillo es un anillo monocíclico, parcial o totalmente saturado de 5, 6, 7 u 8 miembros opcionalmente sustituido con uno o más Ra y/o Rb. En una realización, el anillo monocíclico, saturado de 5, 6, 7 u 8 miembros es ciclopentano, pirrolidina, imidazolidina, 1,3-dioxolano, oxazolidina, tetrahidrofurano, ciclohexano, morfolina, piperidina, dioxano, oxatiazinano, piperazina, cicloheptano, ciclohepteno, azepano, tetrahidroazepina, diazepano, ciclooctano, cicloocteno, azocano, hexahidroazocina, diazocano o hexahidrodiazocina; opcionalmente sustituido con uno o más Ra y/o Rb. Para cada uno de las realizaciones anteriores, en las que R2b y R2c se toman junto con los carbonos a los que están unidos para formar un anillo monocíclico, saturado de 5, 6, 7 u 8 miembros, hay una realización más específica en la que hay 0, 1, 2 o 3 cada uno de Ra y Rb, y Ra es alquilo C1-6; y cada Rb es independientemente para cada aparición =O, -ORa, haloalquiloxi C1-3, -SRa, -N(Rc)2, halo, -CF3, -CN, -S(O)2Ra, C(O)Ra, -CO2Ra, -C(O)N(Rc)2, o -C(Ra)2-N(Rc)2. Por ejemplo, en una realización, hay al menos un Rb que es =O; y opcionalmente un Ra que es alquilo C1-6 opcionalmente sustituido. En esta realización se abarcan compuestos tales como IV-45, IV-46 y IV-47 (véase Tabla IV).
imagen18
Una realización es un compuesto de fórmula estructural IB3, en la que X es O e Y es NR1. En una realización, R5 es halo o alquilo C1-6; Z1 es CH, C-Halo o C-alquilo C1-6 opcionalmente sustituido; y Z2 es CH. En otra realización, R2a es H; y R5 es F o CH3. En una realización más específica, cada uno de R2b y R2c es independientemente para cada aparición H, alquilo C1-6, -ORa, -OCF3, -SRa, -N(Rc)2, halo, -OCF2H, -OCH2F, -CF3, -CN, -S(O)2Ra, -C(O)Ra, -CO2Ra, C(O)N(Rc)2, -C(Ra)2-N(Rc)2 o -[N(Ra)C(O)]nRa; y uno de R2b y R2c no es H. En otra realización, cada uno de R2b y R2c es independientemente para cada aparición H, alquilo C1-6, -N(Rc)2, halo, -CF3, -CN, -S(O)2Ra, -C(O)Ra, -CO2Ra, C(O)N(Rc)2, o -C(Ra)2-N(Rc)2. En una realización más específica R2b es H, halo, -CF3, -CN o -CH3; y R2c es -N(Rc)2, S(O)2Ra, -C(O)N(Rc)2 o -C(Ra)2-N(Rc)2. En otra realización, R2b es H, halo, -CF3, -CN o -CH3; y R2c es -N(Rc)2 o C(Ra)2-N(Rc)2.
Otra realización es un compuesto de fórmula estructural IB3, en la que X es O; Y es NR1; Z1 es CH, C-Halo o Calquilo C1-6 opcionalmente sustituido; Z2 es CH; R2c y R2d son H; y R5 es F o CH3, R2b y R2c se toman junto con los carbonos a los que están unidos para formar un anillo mono o bicíclico, parcial o totalmente saturado de 4-10 miembros, que contiene opcionalmente uno o más heteroátomos y opcionalmente sustituido con uno o más Ra y/o Rb. En una realización, el anillo es un anillo monocíclico parcial o totalmente saturado de 5, 6, 7 u 8 miembros
17
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
Tabla II
Cpd
X Y Z1 R5 R2a R2b R2c R2d
II-1
O NH CH CH3 H H -N(CH3)2 H
II-2
O NH CH CH3 H H H
II-3
O NH CH CH3 H H 1-metil-1,4-diazepan-4-ilo H
II-4
O N-(n-propil) CH CH3 H H 1-metilpiperazin-4-ilo H
II-5
O N-(n-propil) CH CH3 H H imagen44 H
II-6
O NH CH CH3 H H 4-metilpiperidin-1-ilo H
II-7
O N-(isopropil) CH CH3 H H 1-metilpiperazin-4-ilo H
II-8
O NH CH CH3 H H imagen44 H
II-9
O NH CH CH3 H H H
II-10
O NH CH CH3 H H piperazin-1-ilo H
II-11
O NH CH CH3 H H imagen45 H
II-12
O NH CH CH3 H H H
II-13
O NH CH CH3 H H 1-metilpiperazin-4-ilo H
II-14
O NH CH F H H 1-metilpiperazin-4-ilo H
II-15
NH NH CH CH3 H H 1-metilpiperazin-4-ilo H
II-16
NH NH CH F H H 1-metilpiperazin-4-ilo H
II-17
O NH CH CH3 H H morfolin-4-ilo H
II-18
O NH CH F H H morfolin-4-ilo H
II-19
NH NH CH F H H morfolin-4-ilo H
II-20
NCH3 NCH3 CH CH3 H H 1-metilpiperazin-4-ilo H
II-21
NCH3 NCH3 CH F H H 1 -metilpiperazin-4-ilo H
II-22
O NCH3 CH CH3 H H 1-metilpiperazin-4-ilo H
II-23
NCH3 O CH CH3 H H 1-metilpiperazin-4-ilo H
II-24
O NCH3 CH F H H 1-metilpiperazin-4-ilo H
II-25
NH O CH CH3 H H 1-metilpiperazin-4-ilo H
II-26
O NH CH CH3 H CH3 1-metilpiperazin-4-ilo H
II-27
NH NH CH CH3 H CH3 1-metilpiperazin-4-ilo H
II-28
O NH CH CH3 H CH3 H
43
II-29
O NH CH F H CH3 H
II-30
O NH CH F H CH3 1-metilpiperazin-4-ilo H
II-31
O NH CH CH3 H H H
II-32
O NH CH CH3 H H H
II-33
O NH CH F H H H
II-34
O NH CH F H H H
II-35
O NH CH CH3 H H -N(H)-1-metilpiperidin-4-ilo H
II-36
O NH CH CH3 H H -N(H)-piperidin-4-ilo H
II-37
O NH CH CH3 H H H
II-38
O NH CH CH3 H H H
II-39
O NH CH CH3 H CF 3 1-metilpiperazin-4-ilo H
II-40
O NH CH CH3 H F H
II-41
O NH CH CH3 H H H
II-42
O NH CH CH3 H H H H
II-43
O NH CH CH3 H H S(O)2CH3 H
II-44
O NH CH CH3 H H H
II-45
O NH CH CH3 H H -C(O)-piperazin-1-ilo H
II-46
O NH CH CH3 H H H
II-47
O NH CH CH3 H H H
44
II-48
O NH CH CH3 H F H
II-49
O NH CH CH3 H F H
II-50
O NH CH CH3 H F H
II-51
O NH CH CH3 H F H
II-52
O NH CH CH3 H F H
II-53
O NH CH CH3 H F H
II-54
O NH CH CH3 H F H
II-55
O NH CH CH3 H H H
II-56
O NH CH CH3 H H H
II-57
O NH CH CH3 H H H
II-58
O NH CH CH3 H H H
II-59
O NH CH CH3 H H 4,4-difluoropiperidin-1-ilo H
II-60
O NH CH CH3 H H 4,4-dimetilpiperidin-1-ilo H
II-61
O NH CH CH3 H CH3 imagen44 H
II-62
O NH CH CH3 H CH3 H
II-63
O NH CH CH3 H CH3 H
45
II-64
O NH CH CH3 H CH3 H
II-65
O NH CH CH3 H CH3 H
II-66
O NH CH CH3 H CH3 H
II-67
O NH CH CH3 H CH3 imagen44 H
II-68
O NH CH CH3 H CH3 H
II-69
O NH CH CH3 H CH3 H
II-70
O NH CH CH3 H H H
II-71
O NH CH CH3 H H pirrolidin-1-ilo H
II-72
O NH CCH3 CH3 H H 1-metilpiperazin-4-ilo H
II-73
O NH CCH3 CH3 H H morfolin-4-ilo H
II-74
O NH CH CH3 H H -N(H)CH2-ciclopropil H
II-75
O NH CF CH3 H H 1-metilpiperazin-4-ilo H
II-76
O NH CF CH3 H H morfolin-4-ilo H
II-77
O NH CH CH3 H Br H H
II-79
O NCH3 CH CH3 H H -N(H)S(O)2CH3 H
II-80
O NH CH CH3 H H H
II-81
O NH CH CH3 H H H
II-82
O NH CH CH3 H H H
II-83
O NH CH CH3 H H H
II-84
O NH CH CH3 H H H
II-85
O NH CH CF3 H H 1-metilpiperazin-4-ilo H
II-86
O NH CH CH3 H H H
46
11-87
O NH CH CH3 H H H
11-88
O NH CH CH3 H H H
11-89
O NH CH CH3 H H imagen44 H
11-90
O NH CH CH3 H H H
11-91
O NH CH CH3 H H H
II-92
O NH CH CH3 H H H
II-94
O NH CH CH3 H H H
II-95
O NH CH CH3 H H H
II-96
O NH CH CH3 H H H
II-97
O NH CH CH3 H H H
II-98
O NH CH CH3 H H H
II-99
O NH CH CH3 H H H
II-100
O NH CH CH3 H H imagen44 H
II-101
O NH CH CH3 H H H
47
II-102
O NH CH CH3 H H H
II-103
O NH CH CH3 H H H
II-104
O NH CH CH3 H H H
II-105
O NH CH CH3 H H H
II-106
O NH CH CH3 H H imagen46 H
II-107
O NH CH CH3 H H H
II-108
O NH CH CH3 H H H
II-109
O NH CH CH3 H CF 3 imagen44 H
II-110
O NH CH CH3 H CF 3 1-etilpiperazin-4-ilo H
II-111
O NH CH CH3 H F 1-metilpiperazin-4-ilo H
II-112
O NH CH CH3 H F H
II-113
O NH CH CH3 H F H
II-114
O NH CH CH3 H F 1-etilpiperazin-4-ilo H
II-115
O NH CH CH3 H CN H
11-116
O NH CH CH3 H Cl 1 -metilpiperazin-4-ilo H
48
II-117
O NH CH CH3 H H H
11-118
O NH CH CH3 H Cl imagen44 H
II-119
O NH CH CH3 H CF 3 H
11-120
O NH CH CH3 H H imagen44 H
II-121
O NH CH CH3 H H H
II-122
O NH CH CH3 H Cl H
II-123
O NH CH CH3 H H -OCH3 H
II-124
O NH CH CH3 H CF3 imagen44 H
II-125
O NH CH CH3 H F H
II-126
O NH CH CH3 H H H
II-127
O NH CH CH3 H H H
II-128
O NH CH CH3 H H H
II-129
O NH CH CH3 H H imagen47 H
II-130
O NH CH CH3 H H H
II-131
O NH CH CH3 H H H
49
II-132
O NH CH CH3 H H H
II-133
O NH CH CH3 H H H
II-134
O NH CH CH3 H H H
II-135
O NH CH CH3 H H imagen44 H
II-136
O NH CH CH3 H H 1-isopropilpiperazin-4-ilo H
II-137
O NH CH CH3 H H H
II-138
O NH CH CH3 H H H
II-139
O NH CH CH3 H H H
11-140
O NH CH CH3 H OCH3 OCH3 H
II-141
O NH CH CH3 H OCH3 OCH3 H
II-142
O NH CH CH3 H H OCH2CH2OH H
II-143
O NH CH CH3 CH3 H 1 -metilpiperazin-4-ilo H
II-144
O NH CH CH3 H H OCH(CH3)2 H
II-145
O NH CH CH3 H H OCH2CH2OCH3 H
11-146
O NH CH CH3 H H OC(CH3)2C(O)NH2 H
II-147
O NH CH CH3 H CF 3 OCH3 H
11-148
O NH CH CH3 H H OCH2CH2CH2OH H
II-149
O NH CH CH3 H H OCH2CH2CH2OCH3 H
II-150
O NH CH CH3 H Cl H
II-151
O NH CH CH3 H H H
II-152
O NH CH CH3 H OCH3 H H
II-153
O NH CH CH3 H CH3 CH3 H
50
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65
imagen66
imagen67
imagen68
imagen69
imagen70
imagen71
imagen72
imagen73
imagen74
imagen75
imagen76
imagen77
imagen78
imagen79
imagen80
imagen81
imagen82
imagen83
imagen84
imagen85
imagen86
imagen87
imagen88
imagen89
imagen90
imagen91
imagen92
imagen93
imagen94
imagen95
imagen96
imagen97
imagen98
imagen99
imagen100
imagen101
imagen102
imagen103
imagen104
imagen105
imagen106
imagen107
imagen108
imagen109
imagen110
imagen111
imagen112
imagen113
imagen114
imagen115
imagen116
imagen117
imagen118
imagen119
imagen120
imagen121
imagen122
imagen123
imagen124
imagen125
imagen126
imagen127
imagen128
imagen129
imagen130
imagen131
imagen132
imagen133
imagen134
imagen135
imagen136
imagen137
imagen138
imagen139
imagen140
imagen141
imagen142
imagen143
imagen144
imagen145
imagen146
imagen147

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    I-65 N2-((3-metilsulfonil)fenil)-N4-(3-metil-2-oxo-2,3-dihidrobenzo[d]oxazol-6-il)-5-metilpirimidin-2,4-diamina; I-66 N2-((4-metilsulfonil)fenil)-N4-(3-metil-2-oxo-2,3-dihidrobenzo[d]oxazol-6-il)-5-metilpirimidin-2,4-diamina; I-69 N2-((3-metilsulfonil)fenil)-N4-(3-metil-2-oxo-2,3-dihidrobenzo[d]oxazol-5-il)-5-metilpirimidin-2,4-diamina; I-70 N2-((4-metilsulfonil)fenil)-N4-(3-metil-2-oxo-2,3-dihidrobenzo[d]oxazol-5-il)-5-metilpirimidin-2,4-diamina; I-77 N2-((3-metilsulfonil)fenil)-N4-(3-metil-2-oxo-2,3-dihidrobenzo[d]oxazol-5-il)-5-fluoropirimidin-2,4-diamina; I-78 N2-((4-metilsulfonil)fenil)-N4-(3-metil-2-oxo-2,3-dihidrobenzo[d]oxazol-5-il)-5-fluoropirimidin-2,4-diamina; I-100 N2-((3-metilsulfonil)fenil)-N4-(2-oxo-2,3-dihidrobenzo[d]oxazol-6-il)-5-metilpirimidin-2,4-diamina; I-101 N2-((4-metilsulfonil)fenil)-N4-(2-oxo-2,3-dihidrobenzo[d]oxazol-6-il)-5-metilpirimidin-2,4-diamina; I-106 sal trifluoroacetato de N4-(benzoxazolin-2-on-5-il)-N2-(3-trifluorometoxifenil)-5-metilpirimidin-2,4-diamina; I-107 sal trifluoroacetato de N4-(benzoxazolin-2-on-5-il)-N2-(3-trifluorometoxifenil)-5-fluoropirimidin-2,4-diamina; I-108 sal trifluoroacetato de N4-(benzoxazolin-2-on-5-il)-N2-(4-trifluorometoxifenil)-5-metilpirimidin-2,4-diamina; I-109 sal trifluoroacetato de N4-(benzoxazolin-2-on-5-il)-N2-(4-trifluorometoxifenil)-5-fluoropirimidin-2,4-diamina; I-110 N4-(benzoxazolin-2-on-5-il)-N2-[3-trifluorometil-4-(4-etilpiperazin-1-il)fenil]-5-metilpirimidin-2,4-diamina; I-111 N4-(benzoxazolin-2-on-5-il)-N2-[3-metil-4-(4-metilpiperazin-1-il)fenil]-5-metilpirimidin-2,4-di-amina; I-115 N4-(benzoxazolin-2-on-5-il)-N2-(3,4,5-trimetoxifenil)-5-fluoropirimidin-2,4-diamina; I-116 N2-(3-(difluorometoxi)-4-metoxifenil)-N4-(benzo[d]oxazol-2(3H)-on-5-il)-5-metilpirimidin-2,4-diamina; I-117 N4-(benzo[d]oxazol-2(3H)-on-5-il)-N2-(4-trifluorometilsulfonil)fenil-5-metilpirimidin-2,4-diamina; I-118 N4-(benzo[d]oxazol-2(3H)-on-5-il)-N2-(3-trifluorometilsulfonil)fenil-5-metilpirimidin-2,4-diamina; I-119 N4-(benzo[d]oxazol-2(3H)-on-5-il)-N2-(3,4,5-trimetoxi)fenil-5-metilpirimidin-2,4-diamina; I-120 N4-(benzo[d]oxazol-2(3H)-on-5-il)-N2-((4-(1,4-diazabiciclo[3.2.2]nonan-4-il)-3-metil)fenil)-5-metilpirimidin-2,4diamina; I-121 N4-(benzo[d]oxazol-2(3H)-on-5-il)-N2-(4-(8-metil-8-azabiciclo[3.2.1]octan-3-ilamino)fenil)-5-metilpirimidin-2,4diamina; I-122 N4-(benzo[d]oxazol-2(3H)-on-5-il)-N2-((4-(dihidro-1H-pirido[1,2-a]pirazin-2(6H,7H,8H,9H,9aH)-il)-3-metil)fenil) 5-metilpirimidin-2,4-diamina; I-123 N4-(benzo[d]oxazol-2(3H)-on-5-il)-N2-(4-(8-metil-2,8-diazabiciclo[3.2.1]octan-2-il)fenil)-5-metil-pirimidin-2,4diamina; I-124 N4-(benzo[tf]oxazoNn-2(3H)-ona-5-il)-5-metil-N2-[3-(morfoNn-4-il)-4-trifluorometoxifenil]-2,4-pirimidindiamina; I-125 N4-(benzo[d]oxazolm-2(3H)-on-5-il)-N2-[3-trifluorometil-2-(4-metilpiperazm-1-il)piridin-5-il]-5-metilpirimidin-2,4 diamina; I-126 ácido 4-[5-Metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzoico; I-127 N-(2-Dietilamino-etil)-4-[5-metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzamida; I-128 5-{2-[4-(3-Dietilamino-pirrolidin-1-carbonil)-fenilamino]-5-metil-pirimidin-4-ilamino}-3H-benzooxazol-2-ona; I-129 5-[2-(4-Acetil-fenilamino)-5-metil-pirimidin-4-ilamino]-3H-benzooxazol-2-ona; I-130 5-[2-(3-Acetil-fenilamino)-5-metil-pirimidin-4-ilamino]-3H-benzooxazol-2-ona; I-131 2-Metil-5-[5-metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzonitrilo; I-132 N,N-Dimetil-4-[5-metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzamida; I-133 N-Metil-4-[5-metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzamida; I-134 sal formiato de N-ciclopropil-4-[5-metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzamida; I-135 4-[5-Metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-N-fenil-benzamida; I-136 4-[5-Metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-2-pirrolidin-1-il-benzamida; I-137 N-Etil-4-[5-metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzamida; I-138 sal del ácido N-Ciclobutil-4-[5-metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzamida formico; I-139 N-Isopropil-4-[5-metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzamida; I-140 sal formiato de N-ciclopropil-4-[5-metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzamida; I-141 2-Cloro-4-[5-metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzamida; I-142 sal del ácido N-ciclopropil-4-[5-metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]benzamida trifluoroacético; I-143 N-Ciclopropil-4-[5-metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzamida; I-144 N-Ciclobutil-4-[5-metil-4-(2-oxo-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzamida; I-145 4-[5-Metil-4-(2-oxo-3-propionil-2,3-dihidro-benzooxazol-5-ilamino)-pirimidin-2-ilamino]-benzamida; I-146 (5-(2-(4-carbamoilfenilamino)-5-metilpirimidin-4-ilamino)-2-oxobenzo[d]oxazol-3(2H)-il)metilfosfato de di-tercbutilo; I-147 dihidrogenofosfato de (5-(2-(4-carbamoilfenilamino)-5-metilpirimidin-4-ilamino)-2-oxobenzo [d]oxazol-3(2H)il)metilo; I-148 (5-(2-(4-carbamoilfenilamino)-5-metilpirimidin-4-ilamino)-2-oxobenzo[d]oxazol-3(2H)-il)metilfosfato sódico; I-150 dihidrogenofosfato de (5-(2-(4-(ciclobutilcarbamoil)fenilamino)-5-metilpirimidin-4-ilamino)-2-oxobenzo[d] oxazol3(2H)-il)metilo; I-151 (5-(2-(4-(ciclobutilcarbamoil)fenilamino)-5-metilpirimidin-4-ilamino)-2-oxobenzo[d]oxazol-3(2H)-il)metilfosfato de metilo; I-152 (5-(2-(4-(ciclobutilcarbamoil)fenilamino)-5-metilpirimidin-4-ilamino)-2-oxobenzo[d]oxazol-3(2H)-il)metilfosfato de di-terc-butilo; I-153 5-[2-(4-Cloro-3-trifluorometil-fenilamino)-5-metil-pirimidin-4-ilamino]-3H-benzooxazol-2-ona;
    156
    imagen6
    imagen7
    imagen8
    imagen9
    imagen10
    imagen11
    imagen12
    imagen13
    imagen14
    imagen15
    imagen16
    imagen17
    imagen18
ES10701189.2T 2009-01-23 2010-01-22 Composiciones y métodos para la inhibición de la ruta de JAK Active ES2555491T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14705909P 2009-01-23 2009-01-23
US147059P 2009-01-23
US24163009P 2009-09-11 2009-09-11
US241630P 2009-09-11
PCT/US2010/021856 WO2010085684A1 (en) 2009-01-23 2010-01-22 Compositions and methods for inhibition of the jak pathway

Publications (1)

Publication Number Publication Date
ES2555491T3 true ES2555491T3 (es) 2016-01-04

Family

ID=42091548

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12195147.9T Active ES2473584T3 (es) 2009-01-23 2010-01-22 Composiciones y métodos para la inhibición de la ruta de JAK
ES10701189.2T Active ES2555491T3 (es) 2009-01-23 2010-01-22 Composiciones y métodos para la inhibición de la ruta de JAK

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES12195147.9T Active ES2473584T3 (es) 2009-01-23 2010-01-22 Composiciones y métodos para la inhibición de la ruta de JAK

Country Status (24)

Country Link
US (13) US8324200B2 (es)
EP (2) EP2565193B1 (es)
JP (1) JP5802136B2 (es)
KR (1) KR101762967B1 (es)
CN (1) CN102356075B (es)
AU (1) AU2010206683B2 (es)
BR (1) BRPI1006942A2 (es)
CA (1) CA2749217C (es)
DK (2) DK2389372T3 (es)
EA (1) EA022802B1 (es)
ES (2) ES2473584T3 (es)
HK (2) HK1163076A1 (es)
HR (2) HRP20140454T1 (es)
HU (1) HUE026315T2 (es)
IL (1) IL214208A (es)
MX (1) MX2011007750A (es)
NZ (1) NZ594323A (es)
PE (2) PE20110924A1 (es)
PL (2) PL2565193T3 (es)
PT (2) PT2565193E (es)
SG (2) SG2014005318A (es)
SI (2) SI2389372T1 (es)
SM (2) SMT201400071B (es)
WO (1) WO2010085684A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105348203B (zh) 2005-06-08 2018-09-18 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2565193B1 (en) * 2009-01-23 2014-03-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP5732453B2 (ja) * 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US8343954B2 (en) * 2010-07-28 2013-01-01 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EA022623B1 (ru) 2010-10-06 2016-02-29 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные бензимидазола в качестве ингибиторов pi3-киназ
US9115133B2 (en) 2011-03-22 2015-08-25 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
EP2694486B1 (en) 2011-04-01 2018-01-10 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
WO2012135800A1 (en) * 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
EP2696869B1 (en) 2011-04-12 2017-08-23 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
EP2554544A1 (en) * 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
CA2858787C (en) 2011-12-15 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of tertiary amine compounds
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
ES2717279T3 (es) 2012-08-17 2019-06-20 Concert Pharmaceuticals Inc Baricitinib deuterada
JP2015529242A (ja) 2012-09-21 2015-10-05 アドヴィヌス セラピューティクス リミテッドＡｄｖｉｎｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 置換された縮合三環式化合物、組成物およびその医薬用途
WO2014055928A2 (en) 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
CA2887465A1 (en) 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
CN103788066A (zh) * 2012-10-31 2014-05-14 韩冰 一类保护移植器官的化合物及其用途
EP2948150A1 (en) * 2013-01-25 2015-12-02 Rigel Pharmaceuticals, Inc. Compounds and methods for treating inflammatory bowel diseases
CN105308033B (zh) 2013-03-14 2018-08-24 特雷罗药物股份有限公司 Jak2和alk2抑制剂及其使用方法
WO2014168986A1 (en) 2013-04-08 2014-10-16 Brown Dennis M Therapeutic benefit of suboptimally administered chemical compounds
US9549988B2 (en) 2013-06-09 2017-01-24 RJS Biologics Pharmaceutical compounds targeted by MIF affinity-tethered moieties
IN2013MU02611A (es) 2013-08-07 2015-06-12 Cadila Healthcare Ltd
CN105017159B (zh) * 2014-04-28 2019-05-17 四川大学 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途
US10314942B2 (en) * 2014-06-30 2019-06-11 Bacterin International, Inc. Manufacture of biomaterial implants via three-dimensional printing technology
WO2016100452A2 (en) * 2014-12-17 2016-06-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
PL3380465T3 (pl) * 2015-11-26 2021-01-25 Novartis Ag Pochodne diaminopirydyny
SG11201900157RA (en) 2016-07-12 2019-02-27 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
AU2017382830A1 (en) * 2016-12-19 2019-06-13 Epizyme, Inc. Amine-substituted heterocyclic compounds as EHMT2 inhibitors and methods of use thereof
EP3571189B1 (en) 2017-01-23 2023-03-29 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
US11672800B2 (en) 2017-04-21 2023-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
KR102628675B1 (ko) * 2017-05-26 2024-01-25 캔써 리서치 테크놀로지 리미티드 벤즈이미다졸론 유래된 bcl6의 저해제
EP3679027A1 (en) * 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
WO2019075265A1 (en) 2017-10-12 2019-04-18 Revolution Medicines, Inc. PYRIDINE, PYRAZINE AND TRIAZINE COMPOUNDS AS ALLOSTERIC INHIBITORS OF SHP2
WO2019099311A1 (en) * 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
MX2020006273A (es) 2017-12-15 2020-09-14 Revolution Medicines Inc Compuestos policiclicos como inhibidores alostericos de shp2.
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN112533602A (zh) 2018-04-05 2021-03-19 大日本住友制药肿瘤公司 Axl激酶抑制剂及其用途
US20210198248A1 (en) * 2018-05-24 2021-07-01 Astrazeneca Ab Fumarate salt of 5-((5-methyl-2-((3,4,5-trimethylphenyl)amino)pyrimidin-4-yl)amino)-benzo[d]oxazol-2(3h)-one
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
EP3935050A4 (en) 2019-03-06 2023-01-04 C4 Therapeutics, Inc. HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT
MX2022001596A (es) 2019-08-08 2022-03-11 Rigel Pharmaceuticals Inc Compuestos y metodos para tratar sindrome de liberacion de citocinas.
TW202207934A (zh) 2020-03-27 2022-03-01 瑞典商阿斯特捷利康公司 用於肺遞送的乾粉配製物及使用方法
CN113549018B (zh) * 2020-04-24 2024-02-27 中国药科大学 蛋白激酶抑制剂及其衍生物，制备方法、药物组合物和应用
CA3180623A1 (en) * 2020-05-29 2021-12-02 Changyou MA Pyrimidine compound as axl inhibitor
WO2022188735A1 (en) * 2021-03-08 2022-09-15 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as hpk1 inhibitors
CN116178434A (zh) * 2021-11-26 2023-05-30 南京正大天晴制药有限公司 Axl激酶抑制剂的单对甲苯磺酸盐及其晶型
CN116178433A (zh) * 2021-11-26 2023-05-30 南京正大天晴制药有限公司 Axl激酶抑制剂的盐及其制备方法和用途

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
ES2087911T3 (es) 1989-04-28 1996-08-01 Riker Laboratories Inc Dispositivo de inhalacion de polvo seco.
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
IE66203B1 (en) 1989-12-04 1995-12-13 Searle & Co System for transdermal albuterol administration
US5364833A (en) 1990-05-09 1994-11-15 Basf Aktiengesellschaft Cyclohexenone oxime ethers, their preparation and their use as herbicides
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US5492112A (en) 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
US5327883A (en) 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US6060069A (en) 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
US5277195A (en) 1992-02-03 1994-01-11 Dura Pharmaceuticals, Inc. Portable spirometer
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
SK279327B6 (sk) 1992-10-19 1998-10-07 Dura Pharmaceuticals Zariadenie na vytváranie aerosolu z práškového lie
ES2154673T3 (es) 1993-01-29 2001-04-16 Aradigm Corp Suministro intrapulmonar de hormonas.
US6131567A (en) 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
PT748213E (pt) 1994-03-07 2004-08-31 Nektar Therapeutics Metodos e composicoes para administracao pulmonar de insulina
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5622166A (en) 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
WO1999033846A2 (en) 1997-12-31 1999-07-08 The University Of Kansas Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
WO2001051030A1 (en) 2000-01-10 2001-07-19 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003265336B8 (en) 2002-07-29 2009-04-23 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
PL1656372T3 (pl) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
PT2287156E (pt) 2003-08-15 2013-08-26 Novartis Ag 2,4-di(fenilamino)-pirimidinas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
ATE451381T1 (de) 2005-01-19 2009-12-15 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CN105348203B (zh) 2005-06-08 2018-09-18 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US7713987B2 (en) * 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
AU2007276369A1 (en) * 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as JAK kinases inhibitors
GB0615619D0 (en) * 2006-08-05 2006-09-13 Astrazeneca Ab Chemical process for preparation of intermediates
DK2089369T3 (da) * 2006-10-19 2011-05-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2009063240A1 (en) * 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
EP2565193B1 (en) * 2009-01-23 2014-03-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
US8343954B2 (en) * 2010-07-28 2013-01-01 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway

Also Published As

Publication number Publication date
SMT201400071B (it) 2014-07-07
US9566283B2 (en) 2017-02-14
JP2012515793A (ja) 2012-07-12
US9084795B2 (en) 2015-07-21
SI2565193T1 (sl) 2014-07-31
CN102356075A (zh) 2012-02-15
US20140221352A1 (en) 2014-08-07
US20170137411A1 (en) 2017-05-18
US8530656B2 (en) 2013-09-10
US10005767B2 (en) 2018-06-26
CA2749217C (en) 2017-03-21
KR20110111496A (ko) 2011-10-11
AU2010206683A1 (en) 2011-08-11
HK1163076A1 (zh) 2012-09-07
HRP20140454T1 (hr) 2014-06-20
CN102356075B (zh) 2015-06-10
HRP20151325T1 (hr) 2016-01-01
ES2473584T3 (es) 2014-07-07
EA022802B1 (ru) 2016-03-31
NZ594323A (en) 2013-05-31
PL2389372T3 (pl) 2016-02-29
SG2014005318A (en) 2014-03-28
KR101762967B1 (ko) 2017-07-28
US9248132B2 (en) 2016-02-02
US20180265503A1 (en) 2018-09-20
US8735400B2 (en) 2014-05-27
JP5802136B2 (ja) 2015-10-28
IL214208A (en) 2015-08-31
HK1183023A1 (en) 2013-12-13
EP2565193A1 (en) 2013-03-06
PT2389372E (pt) 2016-01-07
EP2389372A1 (en) 2011-11-30
US20100190770A1 (en) 2010-07-29
SG172885A1 (en) 2011-08-29
EA201190082A1 (ru) 2012-02-28
SMT201500308B (it) 2016-01-08
MX2011007750A (es) 2011-09-29
PE20150621A1 (es) 2015-05-07
EP2389372B1 (en) 2015-09-09
US20140011770A1 (en) 2014-01-09
US8563569B2 (en) 2013-10-22
BRPI1006942A2 (pt) 2016-04-12
CA2749217A1 (en) 2010-07-29
EP2565193B1 (en) 2014-03-19
PT2565193E (pt) 2014-06-05
AU2010206683B2 (en) 2016-05-05
DK2389372T3 (en) 2015-12-14
DK2565193T3 (da) 2014-06-16
US20120046245A1 (en) 2012-02-23
US20120010407A1 (en) 2012-01-12
US20120016122A1 (en) 2012-01-19
HUE026315T2 (en) 2016-06-28
US20120010406A1 (en) 2012-01-12
IL214208A0 (en) 2011-08-31
US20120016131A1 (en) 2012-01-19
US20130310364A1 (en) 2013-11-21
US20200216431A1 (en) 2020-07-09
US10556891B2 (en) 2020-02-11
SI2389372T1 (sl) 2016-02-29
US20150307515A1 (en) 2015-10-29
WO2010085684A1 (en) 2010-07-29
US8507675B2 (en) 2013-08-13
US8563716B2 (en) 2013-10-22
PE20110924A1 (es) 2011-12-24
US8524901B2 (en) 2013-09-03
PL2565193T3 (pl) 2014-07-31
US8324200B2 (en) 2012-12-04

Similar Documents

Publication Publication Date Title
ES2555491T3 (es) Composiciones y métodos para la inhibición de la ruta de JAK
HRP20210433T1 (hr) Spojevi pirazola i postupak za dobivanje i upotrebu spojeva
JP2021020924A5 (es)
CA2430539A1 (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US20200261481A1 (en) A medicament for treating influenza characterized by combining a cap-dependent endonuclease inhibitor and an anti-influenza drug
EP3290424B1 (en) Substituted polycyclic pyridone derivatives and prodrug thereof
US8497263B2 (en) Pyrrolinone derivative and pharmaceutical composition comprising the same
US9527854B2 (en) Compounds and methods for treatment of hypertension
US20040176271A1 (en) Compostions useful as inhibitors of JAK and other protein kinases
JPWO2020242960A5 (es)
US6593357B1 (en) Pyrazole compositions useful as inhibitors of ERK
JP2022533260A (ja) タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用
JP2014522847A5 (es)
US10391100B2 (en) Combination of aurora kinase inhibitors and anti-CD20 antibodies
US20220073518A1 (en) Fused ring derivative having mgat-2 inhibitory activity
ES2712134T3 (es) Moduladores mejorados de la actividad de Hec1 y métodos asociados
US20230059640A1 (en) Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
JP2021533183A (ja) がんおよび免疫障害を治療するための化合物、組成物、方法および使用
US20150297586A1 (en) Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives
CN102890414A (zh) 抗蚀剂组合物和用于生产抗蚀图案的方法
US20150344404A1 (en) Pdk4 inhibitor and use thereof
US4412079A (en) Thiadiazole compounds and methods of using said compounds in agriculture
Baradzenka Synthesis and Reactivity of Low Valent Silicon and Phosphorus Compounds
WO2024051354A1 (zh) 一种苯并咪唑类化合物及其制备方法和应用
US20200262924A1 (en) Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent